Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice
Open Access
- 3 December 2007
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 117 (12), 3857-3867
- https://doi.org/10.1172/jci32405
Abstract
The precise roles of B cells in promoting the pathogenesis of type 1 diabetes remain undefined. Here, we demonstrate that B cell depletion in mice can prevent or delay diabetes, reverse diabetes after frank hyperglycemia, and lead to the development of cells that suppress disease. To determine the efficacy and potential mechanism of therapeutic B cell depletion, we generated a transgenic NOD mouse expressing human CD20 (hCD20) on B cells. A single cycle of treatment with an antibody specific for hCD20 temporarily depleted B cells and significantly delayed and/or reduced the onset of diabetes. Furthermore, disease established to the point of clinical hyperglycemia could be reversed in over one-third of diabetic mice. Why B cell depletion is therapeutic for a variety of autoimmune diseases is unclear, although effects on antibodies, cytokines, and antigen presentation to T cells are thought to be important. In B cell–depleted NOD mice, we identified what we believe is a novel mechanism by which B cell depletion may lead to long-term remission through expansion of Tregs and regulatory B cells. Our results demonstrate clinical efficacy even in established disease and identify mechanisms for therapeutic action that will guide design and evaluation of parallel studies in patients.This publication has 49 references indexed in Scilit:
- Role of Autoantibodies in Type 1 DiabetesFrontiers in Bioscience-Landmark, 2007
- Progression of Autoimmune Diabetes: Slowly Progressive Insulin-Dependent Diabetes Mellitus or Latent Autoimmune Diabetes of AdultAnnals of the New York Academy of Sciences, 2006
- TGF- signaling is required for the function of insulin-reactive T regulatory cellsJournal of Clinical Investigation, 2006
- B Cells in Autoimmune DiabetesThe Review of Diabetic Studies, 2005
- Prevention of Arthritis by Interleukin 10–producing B CellsThe Journal of Experimental Medicine, 2003
- The mechanisms of action of rituximab in the elimination of tumor cellsSeminars in Oncology, 2003
- Effective B Cell Depletion with Rituximab in the Treatment of Autoimmune DiseasesImmunobiology, 2002
- Progression to diabetes in relatives with islet autoantibodies. Is it inevitable?Diabetes Care, 1999
- The Role of Lymphocyte Subsets in Accelerated Diabetes in Nonobese Diabetic–Rat Insulin Promoter–B7-1 (NOD-RIP-B7-1) MiceThe Journal of Experimental Medicine, 1998
- Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylaseNature, 1990